Finance

Lists
Why is PYXS down २.२८%?
Dive Deeper
PYXS:NASDAQ
Pyxis Oncology Inc
US$ २.१४
-२.२८%
(-०.०५०) 1D
US$ २.१५
+०.४३% (+०.००९२)
After hours
Closed: अक्टोबर २, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PYXS...
Open
US$ २.२१
High
US$ २.३१
Low
US$ २.१०
Mkt. cap
१७.८५ करोड
Avg. vol.
११.२३ लाख
Volume
२०.०० लाख
52-wk high
US$ ५.५५
52-wk low
US$ १.०३
EPS
-US$ १.४०
Beta
१.३७
Shares outstanding
८.३४ करोड
No. of employees
५६
Open
US$ २.२१
High
US$ २.३१
Low
US$ २.१०
Mkt. cap
१७.८५ करोड
Avg. vol.
११.२३ लाख
Volume
२०.०० लाख
52-wk high
US$ ५.५५
52-wk low
US$ १.०३
EPS
-US$ १.४०
Beta
१.३७
Shares outstanding
८.३४ करोड
No. of employees
५६
News stories
From web sources and news partners
Investing.com
Investing.com
·
२१ घण्टा पहिले
Pyxis Oncology closes $110 million public offering
Investing.com Canada
Investing.com Canada
·
२३ घण्टा पहिले
Form 4 Pyxis Oncology Inc For: 2 October By Investing.com
Stock Titan
Stock Titan
·
२३ घण्टा पहिले
A 10% owner buys $2.90 share-and-warrant packages in Pyxis Oncology (PYXS).
About Pyxis Oncology Inc
CEO-
Employees५६
Founded२०१८
Headquartersबोस्टन, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 7 analysts giving stock ratings to PYXS in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for PYXS in the last 3 months.
Highest
Current US$ २.१४
US$ १९.०० (+७८७.८५%)
Average
US$ ९.०० (+३२०.५६%)
Lowest
US$ ६.०० (+१८०.३७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
US$ ८.००
+२७३.८%
10/01/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
US$ ८.००
+२७३.८%
09/26/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
09/09/2026
Alexandra Ramsey
William Blair
Hold
Reiterated
-
-
09/09/2026
Derek Archila
Wells Fargo
Buy
Reiterated
US$ १९.००
+७८७.९%
09/10/2026
Leonid Timashev
RBC Capital
Buy
Maintained
US$ ६.००
+१८०.४%
09/09/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
US$ ७.००
+२२७.१%
08/17/2026
Robert Driscoll
Wedbush
Buy
Reiterated
US$ ६.००
+१८०.४%
08/14/2026
Unknown Analyst
Guggenheim
Buy
Maintained
US$ ७.००
+२२७.१%
06/29/2026
Last report
२०२६ अगस्ट १३
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ ०.४० / -US$ ०.३५
-१४.२९%miss
Revenue / Est. (USD)
- / २२.२२ हजार
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
१.१० करोड
-
-
Cost of goods sold
-
२३.८८ लाख
-
-
Cost of revenue
-
२३.८८ लाख
-
-
Research and development expenses
१.७८ करोड
२.१७ करोड
२.०० करोड
१.६१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४९.६९ लाख
४५.४२ लाख
३७.४६ लाख
९५.४४ लाख
Operating expense
२.२८ करोड
२.६३ करोड
२.३७ करोड
२.५६ करोड
Total operating expenses
२.२८ करोड
२.८६ करोड
२.३७ करोड
२.५६ करोड
Operating income
-२.२८ करोड
-१.७६ करोड
-२.३७ करोड
-२.५६ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-२.२० करोड
-१.७० करोड
-२.३३ करोड
-२.५३ करोड
EBT excluding unusual items
-२.२० करोड
-१.७० करोड
-२.३३ करोड
-२.५३ करोड
Income tax expense
-
११.०३ लाख
-
-
Effective tax rate
-
-६.४९%
-
-
Other operating expenses
-
-
-
-
Net income
-२.२० करोड
-१.८१ करोड
-२.३३ करोड
-२.५३ करोड
Net profit margin
-
-१६४.०३%
-
-
Earnings per share
-०.३५
-०.२९
-०.३७
-०.४०
Interest and investment income
७.७४ लाख
६.०० लाख
४.५७ लाख
२.५५ लाख
Interest expense
-
-
-
-
Net interest expenses
७.७४ लाख
६.०० लाख
४.५७ लाख
२.५५ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.२२ करोड
-१.४७ करोड
-२.३३ करोड
-२.५३ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू